Special Seminar: Molecularly Programmable Materials for Biological Interfacing

SBME Symposium 2024

Join us and our outstanding community of faculty, trainees, industry and hospital partners, and students as we continue to define the future of health and healthcare at our annual Symposium. • Learn from peers making an impact in the biomedical engineering field. • Discover the latest research.

SBME Symposium 2024


Loading Events

« All Events

  • This event has passed.

Special Seminar: Molecularly Programmable Materials for Biological Interfacing

March 6 @ 11:00 am - 12:00 pm PST

Special Seminar: Molecularly Programmable Materials for Biological Interfacing
Join Virtually:

Seminar Abstract:
The success of medical nanotechnology in response to the recent COVID-19 pandemic has boosted development of nanomaterials for broad diagnostic and therapeutic use. Their size-dependent properties allow us to spy on cellular machinery without introducing much interference. To interact with complex biological systems, engineered nanomaterials require information-rich and autonomous attributes which rely on precise molecular design and engineering of both organization in three-dimensional space, and physicochemical properties imparted by assembled structure. This talk presents engineering efforts of nanomaterials comprise sequence-defined biomolecules to generate high-performing structures at multi-scales and how they can be applied to understand biological processing and nanomedicine. First, I will focus on engineering DNA constructs to organize proteins and nanoparticles into precise and programmable architectures. This part revolves around designs at the interface of molecular and nanoscale objects that impact assembly and reconfiguration behaviors. Next, I will discuss the critical role of peptide molecular designs for an understanding of sequence-structure relationships of disease-associated, plaque-forming amyloid proteins. Further, by integrating with in vivo nanosensor designs, I will show that engineered peptides can act as multiplexed synthetic biomarkers to reveal aberrant activities in the disease microenvironments and for non-invasive diagnostics of lung cancer.
Dr. Shih-Ting (Christine) Wang's headshot
Dr. Shih-Ting (Christine) Wang’s Bio:
Dr. Shih-Ting (Christine) Wang is postdoctoral associate in the lab of Dr. Sangeeta Bhatia in the Koch Institute and fellow of the Ludwig Cancer Center at the Massachusetts Institute of Technology. Her current project focuses on the development of in vivo activity-based nanosensors for non-invasive detection of lung cancer and infection. Prior to this, she was a research associate in the lab of Dr. Oleg Gang at Brookhaven National Laboratory, where she worked on DNA nanotechnology for protein lattice engineering and nanomedicine applications. Wang completed her Ph.D. research in the lab of Dr. Molly Stevens on type II diabetes-related biosensing and amyloid fibrillation. From 2016 to 2020, she has been a facility user and collaborated on multiple research projects with the Molecular Foundry at Lawrence Berkeley National Laboratory.


March 6
11:00 am - 12:00 pm PST
Event Categories:


View Organizer Website


2329 West Mall
Vancouver, BC V6T 1Z4 Canada
+ Google Map